Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00781
|
|||||
| Drug Name |
Mibefradil
|
|||||
| Synonyms |
Calcium T-channel inhibitor (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics; Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer); Mibefradil (Cytostatic Checkpoint Therapy, ovarian cancer), Tau Therapeutics
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Ovarian cancer [ICD11: 2C73] | Withdrawn | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C29H38FN3O3
|
|||||
| Canonical SMILES |
CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F
|
|||||
| InChI |
InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1
|
|||||
| InChIKey |
HBNPJJILLOYFJU-VMPREFPWSA-N
|
|||||
| CAS Number |
CAS 116644-53-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 495.6 | Topological Polar Surface Area | 67.4 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
5.8
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:6920
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000236) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.